In this podcast (14:35), Medicom’s correspondent covers presentations from the European Academy of Dermatology & Venereology (EADV) Congress 2025, held 17–20 September, in Paris, France. Enjoy listening! A large real-world cohort study linked GLP-1 receptor agonist therapy with a higher risk of nonscarring alopecia, particularly telogen effluvium and androgenetic alopecia. The association was evident within six months, highlighting the need for patient counselling and nutritional monitoring. The Scars of Life project, surveying over 30,000 adults worldwide, found that patients with atopic eczema were significantly more likely to experience suicidal thoughts, driven by disease severity, pruritus, stigma, and sleep disturbance. Routine psychological screening in atopic eczema care may be life-saving. A pooled safety analysis of 5 clinical trials showed delgocitinib cream has a consistent and favourable safety profile over 52 weeks, with fewer adverse events than alitretinoin. This topical JAK inhibitor offers a promising option for the difficult-to-treat chronic hand eczema population. 3-year data from the ALLEGRO programme confirmed durable responses to ritlecitinib 50 mg daily in alopecia areata. Nearly 90% of responders maintained regrowth through year 3, with up to 31% achieving complete scalp hair recovery and significant improvements in eyebrow and eyelash regrowth. The BeNeBio pragmatic RCT demonstrated that dose reduction of IL-17 and IL-23 inhibitors in well-controlled plaque psoriasis was non-inferior to usual care, with 75% of patients successfully tapered. IL-23 inhibitors showed the highest tapering success rates, suggesting a sustainable treatment strategy.
Integrating Dermatology and Whole-Patient Care
Across studies, EADV 2025 underscored dermatology’s intersection with systemic health, mental wellbeing, and long-term management. From unexpected drug side effects to psychosocial risks and biologic optimisation, the focus was on holistic, patient-centred care.
Enjoy listening!
Copyright ©2025 Medicom Publishing Group
Posted on
Table of Contents: EADV 2025
Featured articles
Cohort study links GLP-1RAs therapy to elevated risk of nonscarring hair loss
Earlier skin cancer diagnosis and high patient satisfaction with patient-led teledermoscopy
More than skin deep: Atopic eczema linked to higher suicide risk across all ages
Online First
Cohort study links GLP-1RAs therapy to elevated risk of nonscarring hair loss
Psoriasis: Tapering of IL-23 or IL-17 inhibition is non-inferior to usual care
Pooled analysis confirms a consistent safety profile of delgocitinib cream in CHE
Extended-release oral minoxidil: a rising star in the treatment of androgenic alopecia?
Early treatment response predicts long-term stability with tralokinumab in AD
Earlier skin cancer diagnosis and high patient satisfaction with patient-led teledermoscopy
Targeting the OX40 pathway: a novel therapeutic approach in AD
CSU: Rapid symptom relief with remibrutinib
Alopecia areata: ritlecitinib demonstrates sustained efficacy for up to 3 years
Topical ruxolitinib: a new hope for patients with prurigo nodularis?
More than skin deep: Atopic eczema linked to higher suicide risk across all ages
Beyond glycaemic control: GLP-1RAs reduce cardiovascular and psychiatric risk in psoriasis
HS: Promising clinical benefits with izokibep
CHE in adolescents: Delgocitinib cream superior to vehicle
Low ferritin levels in pregnancy are associated with a higher probability of generalised pruritus
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com